Skip to main content
Taylor & Francis Group Logo
Advanced Search

Click here to search books using title name,author name and keywords.

  • Login
  • Hi, User  
    • Your Account
    • Logout
Advanced Search

Click here to search books using title name,author name and keywords.

Breadcrumbs Section. Click here to navigate to respective pages.

Book

Pharmacoepidemiology

Book

Pharmacoepidemiology

DOI link for Pharmacoepidemiology

Pharmacoepidemiology book

Pharmacoepidemiology

DOI link for Pharmacoepidemiology

Pharmacoepidemiology book

Edited ByStanley A. Edlavitch
Edition 1st Edition
First Published 1989
eBook Published 20 December 2018
Pub. Location Boca Raton
Imprint Routledge
DOI https://doi.org/10.1201/9780203743669
Pages 360
eBook ISBN 9780203743669
Subjects Bioscience
Share
Share

Get Citation

Edlavitch, S.A. (Ed.). (1989). Pharmacoepidemiology (1st ed.). CRC Press. https://doi.org/10.1201/9780203743669

ABSTRACT

This volume is comprised of papers presented at the Third International Conference on Pharmacoepidemiology, held September 9-11, 1987, in Minneapolis, Minnesota. The book is divided into four sections, which reflect the four themes of the conference: Social Impact of Pharmacoepidemiology; Drug Epidemiology and the Law; Drug Surveillance; and Drugs, Populations, and Outcomes: Specific Studies. The collection of papers discusses the social and legal impact of epidemiology, the system of checks and balances that is necessary for the field, the importance of core support for researchers, and the goal of an enlightened and informed public, including the media, consumer advocates, and the courts. Contributing authors offer perspectives from academia, practice, government, industry and the law. Numerous tables and figures are included to illustrate many of the papers within the text. This book offers substantial reading for epidemiologists and individuals interested in the field of pharmacoepidemiology.

TABLE OF CONTENTS

section One|50 pages

Social Impact of Pharmacoepidemiology

chapter |1 pages

Introduction

ByStanley A. Edlavitch

chapter 1|17 pages

Pharmacoepidemiology and Public Policy

ByDavid H. Lawson

chapter 2|19 pages

Risk Assessment of New Drugs, Pharmacoepidemiology, and Regulatory Decisionmaking

ByRobert C. Nelson

chapter 3|7 pages

Industry Perspectives and the Contributions of Pharmacoepidemiology to Public Health

ByRoger M. Sachs, Gretchen S. Dieck

section Two|66 pages

Drug Epidemiology and the Law

chapter 4|31 pages

Impact of Drug Products Liability on Needs for Pharmacoepidemiologic Studies and Expertise

BySidney H. Willig

chapter 5|30 pages

Epidemiology in the Courtroom: Anatomy of an Intellectual Embarrassment

ByBarry L. Shapiro, Marc S. Klein

section Three|108 pages

Drug Surveillance

chapter 6|12 pages

A Brief Review of the Yellow Card Adverse Reaction Reporting Scheme in the United Kingdom

ByGraham H. Burton, Ronald D. Mann

chapter 7|11 pages

Frequency Analysis of Spontaneous Reports from Different Countries: The Example of Continental Western Europe

ByRudolf Bruppacher, Rudolf Blattner, Thomas Fisch, Rosemarie Sift, Gary C. Berneker

chapter 8|10 pages

Evaluation of First Year Experience of a State Pilot Project to Promote Physician Reporting of Adverse Drug Events to the Food and Drug Administration

ByAudrey Smith Rogers, Ebenezer Israel, Gerald Faich, Craig R. Smith

chapter 9|7 pages

Monitoring System for Adverse Events Following Immunization: Risk Factors for Convulsions After Vaccination

ByJohn R. Livengood, John R. Mullen

chapter 10|7 pages

Application of a New Method for Adverse Experience Monitoring to Premarketing Studies on Two New Drugs: Some Experiences

ByMari-Ann Wallander, Per Lundborg

chapter 11|19 pages

A Nationwide Drug Surveillance Network

ByThaddeus H. Grasela

chapter 12|6 pages

The Pharmacoepidemiology Data Base of the Brigham and Women’s Hospital

ByScott Stryker

chapter 13|10 pages

Overcoming Limitations of Routine Surveillance of Drug Overdose

ByNewell E. McElwee, Joseph C. Veltri, Mary Catherine Schumacher

chapter 14|3 pages

Current Status of the Saskatchewan Prescription Drug Plan

ByWinanne Downey

chapter 15|5 pages

Early Experience with the COMPASS Data Base

ByJeffrey L. Carson

chapter 16|8 pages

Postmarketing Surveillance in Tayside: A Further Assessment of Record Linkage Using Five Nonsteroidal Antiinflammatory Drugs

ByPaul H.G. Beardon, Sheila V. Brown, Denis G. McDevitt

section Four|128 pages

Drugs, Populations, and Outcomes: Specific Studies

chapter 17|13 pages

Nonsteroidal Antiinflammatory Drugs and Upper Gastrointestinal Bleeding

ByBrian L. Strom, Jeffrey L. Carson

chapter 18|12 pages

Impact of Nonsteroidal Antiinflammatory Agents on General Gastrointestinal Upset in an Elderly Population

ByWayne Bigelow, Ted Collins

chapter 19|6 pages

NSAIDs as a Cause of Morbidity and Mortality from Peptic Ulcer Complications in New South Wales

ByDavid A. Henry, Pamela R. Hall, Anne Johnston, Annette Dobson

chapter 20|11 pages

The Relationship Between Rheumatoid Arthritis and Risk of Cancer, Controlling for the Effect of Drugs, in Hospitalized Patients of Saskatchewan, Canada

ByPatricia Tennis, Elizabeth B. Andrews, Hugh H. Tilson

chapter 21|9 pages

Collaborative Study of the Effects of Acyclovir in Pregnancy

ByElizabeth B. Andrews, Hugh H. Tilson, José F. Cordero, E. Russell Alexander, Katherine M. Stone, Sevgi O. Aral, Michael Rosenberg, Barry Hurn, L. Gray Davis

chapter 22|6 pages

Creutzfeldt-Jakob Disease, Human Growth Hormone, and Its Replacement with Synthetic Growth Hormone

ByPeter G. Bernad

chapter 23|14 pages

Retrovir: The Challenge of Postmarketing Surveillance

ByMichael C. Joseph, Terri Creagh-Kirk

chapter 24|12 pages

Differences in Psychotropic Medications Reported Used by Blacks and Whites

BySharyn R. Batey, Harry H. Wright, Elisabeth A. Cole, Brian Butler

chapter 25|9 pages

The Dunedin Program: A Longitudinal Study of Aging

ByRonald B. Stewart, William E. Hale, Ronald G. Marks

chapter 26|7 pages

Psychotropic Drug Use and Health Outcomes in Nursing Homes

ByElizabeth A. Chrischilles, Mary Nduaguba, Robert B. Wallace, Todd P. Semla

chapter 27|20 pages

What is the Cost of Nephrotoxicity Associated with Aminoglycosides?

ByJohn M. Eisenberg, Harris Koffer, Henry A. Glick, Margaret L. Connell, Larrye E. Loss, George H. Talbot, Neil H. Shusterman, Brian L. Strom
T&F logoTaylor & Francis Group logo
  • Policies
    • Privacy Policy
    • Terms & Conditions
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
    • Cookie Policy
  • Journals
    • Taylor & Francis Online
    • CogentOA
    • Taylor & Francis Online
    • CogentOA
  • Corporate
    • Taylor & Francis Group
    • Taylor & Francis Group
    • Taylor & Francis Group
    • Taylor & Francis Group
  • Help & Contact
    • Students/Researchers
    • Librarians/Institutions
    • Students/Researchers
    • Librarians/Institutions
  • Connect with us

Connect with us

Registered in England & Wales No. 3099067
5 Howick Place | London | SW1P 1WG © 2021 Informa UK Limited